1316741-91-9

Upstream product

• 93964-79-5 2-(RS)-amino-4-phenylbutyric acid ethyl ester hydrochloride 
• 21176-60-3 2-(RS)-amino-4-phenylbutyric acid hydrochloride 
• 5463-92-3 2-acetylamino-2-phenylethylmalonic acid diethyl ester 
• 17376-04-4 2-phenethyl iodide 
• 118-48-9 isatoic anhydride 
• 1316741-89-5 2-(RS)-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}-4-phenylbutyric acid ethyl ester 
• 1316742-32-1 2-(RS)-(2-aminobenzoylamino)-4-phenylbutyric acid ethyl ester 
• 58881-45-1 Indole-2-carbonyl chloride 
• 1477-50-5 Indole-2-carboxylic acid 

Relevant academic research and scientific papers

New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R)

The anthranilic acid diamides represent the most recent class of nonpeptide CCK1 receptor (CCK1-R) antagonists. Herein we describe the second phase of the anthranilic acid C-terminal optimization using nonproteinogenic amino acids containing a phenyl ring in their side chain. The Homo-Phe derivative 2 (VL-0797) enhanced 12-fold the affinity for the rat CCK1-R affinity and 15-fold for the human CCK1-R relative to the reference compound 12 (VL-0395). The eutomer of 2 (6) exhibited a nanomolar range affinity toward the human CCK1-R and was at least 400-fold selective for the CCK1-R over the CCK2-R. Molecular docking in the modeled CCK1-R and its validation by site-directed mutagenesis experiments showed that the 6 binding site overlaps that occupied by the C-terminal bioactive region of the natural agonist CCK. Owing to their interesting properties, new compounds provided by this study represent a solid basis for further advances aimed at synthesis of clinically valuable CCK1-R antagonists.